Given the effects of the depletion of FRβ+ TAMs on endogenous antitumor immune responses, we hypothesized that the combination of mFRβ CAR-T cells with a conventional tumor-targeted CAR might result in enhanced antitumor efficacy. Here, FOLR2 is linked to neoplasm.